ArticleNature communications2026
dioscRi enables transferable prediction of clinical outcomes in multi-parameter cytometry data.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multi-parameter cytometry technologies enable high-dimensional analysis of immune cell populations at single-cell resolution. Deep learning has been widely applied to these datasets, but existing methods often struggle with transferability across datasets due to technical variability, batch effects and identification of biologically relevant cell populations, limiting their utility in clinical research. We present dioscRi, a transferable deep learning framework that integrates a maximum mean discrepancy variational autoencoder for normalization and de-noising, enhancing cross-dataset compatibility. Changes in cell type proportions and marker expression are identified by structuring these features within biologically or empirically derived cell type hierarchies. These hierarchies are incorporated directly into an overlapping group LASSO model, improving the prediction of clinical outcomes. When applied to a coronary artery disease study, dioscRi recapitulated several known immune associations. Benchmarking across multiple datasets demonstrated dioscRi's ability to transfer across cohorts with compatible marker panels and outperform existing methods on three of four datasets, establishing it as an interpretable tool for cytometry data analysis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.